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ESTATE-OF-THE-ART PAPER889Device Therapy in Heart Failure Patients With CKDLeon A. Cannizzaro, Jonathan P. Piccini, Uptal D. Patel, Adrian F. Hernandez
Heart failure and chronic kidney disease (CKD) both carry significant risk for sudden cardiac
death, hospitalization, and mortality; when combined, the risks may be multiplied. However,
many of the major trials demonstrating the benefits of implantable cardioverter-defibrillators
(ICDs) and cardiac resynchronization therapy (CRT) excluded patients with significant CKD.
In this review, Cannizzaro and colleagues discuss the intersection of heart failure and CKD as
it relates to progressive heart failure and the risk of sudden death. There appears to be a need
for dedicated clinical trials and comparative effectiveness studies to identify the appropriate use
of ICD and CRT devices in patients with heart failure and CKD.CLINICAL RESEARCH CLINICAL TRIALS897hANP Infusion May Protect the Renal Function in Patients Undergoing CABGAkira Sezai, Mitsumasa Hata, Tetsuya Niino, Isamu Yoshitake, Satoshi Unosawa, Shinji Wakui,
Haruka Kimura, Motomi Shiono, Tadateru Takayama, Atsushi Hirayama
Sezai and colleagues studied the ability of human atrial natriuretic peptide (hANP) infusion
to prevent acute kidney injury in patients with chronic kidney disease (CKD) undergoing
coronary artery bypass grafting (CABG). Patients with pre-operative CKD (pre-operative
estimated glomerular filtration rate 60 ml/min/1.73 m2) undergoing CABG were
andomized to hANP infusion or placebo. The post-operative serum creatinine was
ignificantly lower in the hANP group not only at 1 month, but also at 1 year. There were
ewer cardiac events and patients receiving chronic dialysis in the hANP group at 1 year.
ANP infusion appears to protect and preserve renal function in patients with CKD
ndergoing CABG.
ditorial Comment: Guido Boerrigter, John C. Burnett, Jr, p. 904(continued on page A-22)
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EINTERVENTIONAL CARDIOLOGY907New Formula for Predicting Safe Amount of Contrast Media in Patients Undergoing PCIHitinder S. Gurm, Simon R. Dixon, Dean E. Smith, David Share, Thomas LaLonde, Adam Greenbaum,
Mauro Moscucci, for the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry
The association between calculated creatinine clearance (CCC)-based contrast dose and the
risk of contrast-induced nephropathy (CIN) and nephropathy requiring dialysis (NRD) was
assessed by Gurm and colleagues in nearly 60,000 patients undergoing percutaneous coronary
intervention (PCI). The risk of CIN and NRD was directly associated with increasing
contrast volume adjusted for CCC. The risk for CIN and NRD approached significance
when the ratio of contrast dose/CCC exceeded 2, and the risk was dramatically elevated in
patients exceeding a ratio of 3. Limiting contrast volume to 3 times the CCC prevents the
vast majority of cases of post-PCI CIN.HEART FAILURE915Impact of Beta-Blockers on Mortality for HF Questioned in U.S. PatientsChristopher M. O’Connor, Mona Fiuzat, Karl Swedberg, Michael Caron, Bruce Koch, Peter E. Carson,
Wendy Gattis Stough, Gordon W. Davis, Michael R. Bristow
O’Connor and colleagues performed a meta-analysis of the large, randomized, double-blind,
placebo-controlled studies that: 1) evaluated beta-blockers in heart failure (HF) patients;
2) had a primary endpoint of mortality; and 3) enrolled U.S. patients. Nearly 9,000 patients
were enrolled in the MERIT-HF (Metoprolol Controlled-Release Randomized Intervention
Trial in Heart Failure), COPERNICUS (Carvedilol Prospective Randomized Cumulative
Survival), and BEST (-Blocker Evaluation of Survival Trial) studies combined; 47% were
rom the United States. The mortality reduction associated with beta-blockade in the U.S.
ohort was small and not statistically significant (relative risk [RR]: 0.92), but the reduction
as significant in the rest of the world cohort (RR: 0.64). The authors conclude by exploring
arious hypotheses to explain these differences, but they arrive at no firm answers.ditorial Comment: Barry M. Massie, p. 923HEART FAILURE925Outcomes of Patients With X-Linked DCM Caused by Defects in the DYS GeneMarta Diegoli, Maurizia Grasso, Valentina Favalli, Alessandra Serio, Fabiana Isabella Gambarin,
Catherine Klersy, Michele Pasotti, Emanuela Agozzino, Laura Scelsi, Alessandra Ferlini, Oreste Febo,
Giovanni Piccolo, Luigi Tavazzi, Jagat Narula, Eloisa Arbustini
Diegoli and colleagues describe the diagnostic work-up, phenotype, and long-term outcomes
of patients with a dilated cardiomyopathy (DCM) associated with genetic defects in the
dystrophin (DYS) gene. Over 400 consecutive male patients with DCM underwent a
standardized evaluation, including a thorough sequencing of the DYS gene. DYS defects
were found in 8%, 90% of whom had proven X-linked inheritance. Most patients also had a
mild skeletal myopathy and/or increased serum creatine phosphokinase (sCPK). During a
median follow-up of 5 years, 23% of these patients underwent transplantation and 26% died of
heart failure, but none had evidence of life-threatening ventricular arrhythmias. DYS-related
DCM should be suspected in male patients with increased sCPK and X-linked inheritance.
(continued on page A-23)
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ECARDIAC RESYNCHRONIZATION THERAPY935Meta-Analysis Confirms Benefit of CRT in Minimally Symptomatic HF PatientsSelcuk Adabag, Henri Roukoz, Inder S. Anand, Arthur J. Moss
Adabag and colleagues performed a systematic review and meta-analysis of prospective
randomized clinical trials of cardiac resynchronization therapy (CRT) versus implantable
cardioverter-defibrillators (ICDs) in patients with reduced ejection fraction (EF), prolonged
QRS interval, and New York Heart Association (NYHA) functional class I to II heart failure
(HF). Data was combined from 5 clinical trials, including 4,317 patients with NYHA
functional class I to II HF. All-cause mortality was significantly reduced with CRT compared
with ICD (relative risk [RR]: 0.81). This benefit was significant for patients with NYHA
functional class II, but not for NYHA functional class I; however, NYHA functional class I
patients had an RR of 0.57 for HF hospitalization with CRT. These results confirm the
benefits of CRT in minimally symptomatic or asymptomatic patients.HEART RHYTHM DISORDERS
942tringency of Rate Control Does Not Affect
Cardiac Remodeling in Patients With Permanent AFMarcelle D. Smit, Harry J. G. M. Crijns, Jan G. P. Tijssen, Hans L. Hillege, Marco Alings,
Ype S. Tuininga, Hessel F. Groenveld, Maarten P. Van den Berg, Dirk J. Van Veldhuisen,
Isabelle C. Van Gelder, for the RACE II Investigators
Smit and colleagues evaluated echocardiographic remodeling in permanent atrial fibrillation
(AF) patients treated with either lenient or strict rate control. Echocardiography was
conducted at baseline and at follow-up in 517 patients randomized to strict heart rate control
(target 80 beats/min) or lenient rate control (target 110 beats/min). Between baseline and
ollow-up, significant adverse atrial or ventricular remodeling was not observed in either
roup. This was also true when stratified by actual achieved heart rates rather than targeted
ates. These results suggest that lenient rate control does not increase the risk of adverse
ardiac remodeling in patients with permanent AF.
ditorial Comment: D. George Wyse, p. 950(continued on page A-25)
AUGUST 23, 2011 (continued) A-25CARDIAC SURGERY953Diastolic Function Strongly Linked to Risk of POAFRowlens M. Melduni, Rakesh M. Suri, James B. Seward, Kent R. Bailey, Naser M. Ammash, Jae K. Oh,
Hartzell V. Schaff, Bernard J. Gersh
Melduni and colleagues investigated whether left ventricular (LV) diastolic dysfunction was an
important risk factor for post-operative atrial fibrillation (POAF) after cardiac surgery.
Patients were residents of Olmsted County, Minnesota, who underwent complete LV
diastolic function assessment prior to cardiac surgery. POAF occurred in 38% of patients.
The rate of POAF increased exponentially with diastolic function grade. LV diastolic
dysfunction is a powerful, independent predisposing substrate for the initiation of POAF;
targeting interventions at the highest-risk groups may help to identify prophylactic measures.VALVULAR HEART DISEASE962Valvular Aortic Stenosis Commonly Develops After Surgery for Subaortic StenosisZachary W. M. Laksman, Candice K. Silversides, Tara Sedlak, Ahmed M. Samman, William G. Williams,
Gary D. Webb, Peter P. Liu
Classic teachings emphasize that patients with discrete subaortic stenosis are at risk for later
aortic regurgitation because the high velocity jet may damage the valve. Laksman and
colleagues reviewed the records of 121 adults with a diagnosis of congenital discrete
fibromuscular subaortic stenosis, most of whom had previously undergone surgery. Valvular
aortic stenosis requiring surgery developed in 26%, while only 3% required surgery for aortic
insufficiency. The risk of developing aortic stenosis was higher in patients with a bicuspid
aortic valve, coarctation of the aorta, and/or supravalvular stenosis.(continued on page A-26)
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966enetically Increasing S100A1 Reverses
Dysfunction of Failing Human CardiomyocytesHenriette Brinks, David Rohde, Mirko Voelkers, Gang Qiu, Sven T. Pleger, Nicole Herzog,
Joseph Rabinowitz, Arjang Ruhparwar, Scott Silvestry, Carolin Lerchenmüller, Paul J. Mather,
Andrea D. Eckhart, Hugo A. Katus, Thierry Carrel, Walter J. Koch, Patrick Most
Translational studies in animal heart failure (HF) models have identified S100A1 as a unique
regulator of an integrative Ca2 controlled network in cardiomyocytes involving sarcoplasmic
reticulum and sarcomeric and mitochondrial functions. Brinks and colleagues obtained
cardiomyocytes from failing human hearts and confirmed lower levels of S100A1; these cells
were then transfected to express higher levels of S100A1. S100A1 gene therapy both reversed
contractile dysfunction and improved contractile reserve under beta-adrenergic receptor
stimulation. S100A1 reversed underlying Ca2 handling abnormalities, improved
mitochondrial function, and restored the phosphocreatine/adenosine-triphosphate (ATP)
ratio. These findings strengthen the rationale for future molecular-guided therapy of human
HF using S100A1.Editorial Comment: Stephen L. Belmonte, Kenneth B. Margulies, Burns C. Blaxall, p. 974PRE-CLINICAL RESEARCH
977ombination of IGF-1 and HGF Stimulates
Endogenous Cardiac Stem Cells After Infarct in Porcine ModelGeorgina M. Ellison, Daniele Torella, Santo Dellegrottaglie, Claudia Perez-Martinez,
Armando Perez de Prado, Carla Vicinanza, Saranya Purushothaman, Valentina Galuppo,
Claudio Iaconetti, Cheryl D. Waring, Andrew Smith, Michele Torella, Carlos Cuellas Ramon,
Jose Manuel Gonzalo-Orden, Valter Agosti, Ciro Indolfi, Manuel Galiñanes, Felipe Fernandez-Vazquez,
Bernardo Nadal-Ginard
Ellison and colleagues tested the ability of a combination of insulin-like growth factor (IGF)-1
and hepatocyte growth factor (HGF) to activate resident endogenous porcine cardiac stem/
progenitor cells (epCSCs) and to promote myocardial repair in a pig model of myocardial
infarction (MI). Acute MI was induced by transient balloon occlusion. IGF-1 and HGF were
then coadministered through the infarct-related artery 30 min after coronary reperfusion.
IGF-1/HGF activated epCSCs increased their myogenic differentiation, improved
cardiomyocyte survival, reduced fibrosis, and were associated with reduced infarct size and
improved ejection fraction at 2 months. These cofactors appear to stimulate epCSCs in a
method that is simpler and more clinically relevant than other attempts to use stem cell
therapy to treat acute MI.
